Nasdaq ardx.

AzurRx, Inc. (NASDAQ:AZRX) said due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 9.09 million ...

Nasdaq ardx. Things To Know About Nasdaq ardx.

WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved XPHOZAH ...Oct 31, 2023 · Ardelyx (ARDX) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.14 per share a year ago. These ... Dec 4, 2023 · Ardelyx has generated ($0.12) earnings per share over the last year ( ($0.12) diluted earnings per share). Earnings for Ardelyx are expected to grow in the coming year, from ($0.31) to ($0.24) per share. Ardelyx has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 ... Ardelyx Inc (NASDAQ:ARDX) trade information. Upright in the red during last session for losing -0.39%, in the last five days ARDX remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $3.86 price level, adding 6.76% to its value on the day.

3 Penny Stocks to Buy and Hold for the Next 10 Years. 1 month ago. Simply Wall St. 1 week ago. Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, …Ardelyx, Inc. Common Stock (ARDX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.

Oct 17, 2023 · WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor for adult patients with CKD on dialysis with hyperphosphatemia. The company will host a conference call on December 29, 2022, at 8:00 AM ET. To participate in the conference call, please call (866) 374-5140 (toll-free) or (404) 400-0571 (toll) and …The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ...Find the latest SEC Filings data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Celebrations may be in order for Ardelyx, Inc. (NASDAQ:ARDX) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The revenue forecast for ...

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for …

Ardelyx (NASDAQ: ARDX). $4.37. (6.8%). $0.28. Price as of November 29, 2023, 4:00 p.m. ET. Jump to: Overview. OverviewReturn vs. S&PCompany InfoNews & Analysis ...

XPeng Inc. American depositary shares, each representing two Class A ordinary shares (XPEV) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global ...On this news, the Company’s stock price fell $0.70, or 13.4%, to close at $4.51 per share on May 26, 2021, on unusually heavy trading volume.Massachusetts-based Ardelyx (NASDAQ:ARDX) is another hot biotech to consider heading into 2023. All after the US FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of ...WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...ARDX Ardelyx Options Ahead of Earnings If you haven`t bought ARDS before it went up 6X: Then analyzing the options chain and the chart patterns of ARDX Ardelyx prior to the earnings report this week, I would consider purchasing the 4usd strike price Calls with an expiration date of 2024-1-19, for a premium of approximately $0.45.AAPL. 189.69. -0.01%. 49.41M. View today's Ardelyx Inc stock price and latest ARDX news and analysis. Create real-time notifications to follow any changes in the live stock price.Track Ardelyx Inc (ARDX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable ...

Shares of Ardelyx ( ARDX 3.20%) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this ...Get Ardelyx Inc. (ARDX) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, financial report, etc.WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Dec 3, 2023 · Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research report issued on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s target price points to a potential upside of 89.08% from the stock’s current price. A number of […] WALTHAM, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Sep. 7, 2023, 04:15 AM. H.C. Wainwright analyst Ed Arce initiated coverage with a Buy rating on Ardelyx ( ARDX – Research Report) today and set a price target of $9.00. The company’s shares ...View Ardelyx, Inc ARDX investment & stock information. Get the latest Ardelyx, Inc ARDX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... NASDAQ data is at least 15 ...

WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Based on analysts offering 12 month price targets for ARDX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...ARDX ARDX AFTER HOURS QUOTE ARDX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...Get Ardelyx Inc. (ARDX) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, financial report, etc.Find the latest historical data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million. Ardelyx (NASDAQ: ARDX) stock is climbing today after the U.S. Food and Drug Administration ( FDA) approved the firm’s treatment for excessive phosphate levels in kidney disease patients. Shares ...Ardelyx Inc (NASDAQ:ARDX) 4.34 Delayed Data As of Nov 17 +0.305 / +7.57% Today’s Change 1.56 Today ||| 52-Week Range 5.13 +52.11% Year-to-Date Quote Profile News …

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Ardelyx Inc. (NASDAQ:ARDX) is a biopharmaceutical company based in Waltham, Massachusetts. The company develops and commercialized medicines to treat gastrointestinal and cardiorenal therapeutic ...

ARDX ARDX AFTER HOURS QUOTE ARDX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...Ardelyx Stock (NASDAQ:ARDX), Short Interest Report. Short interest for Ardelyx gives investors a sense of the degree to which investors are betting on the decline of Ardelyx's stock.Celebrations may be in order for Ardelyx, Inc. (NASDAQ:ARDX) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The revenue forecast for ...Nov 30, 2023 · According to 5 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price forecast is $8.7, which is an increase of 92.91% from the latest price. Ardelyx (NASDAQ: ARDX) stock is climbing today after the U.S. Food and Drug Administration ( FDA) approved the firm’s treatment for excessive phosphate levels in kidney disease patients. Shares ...Aug 17, 2023 · Ardelyx, Inc. (NASDAQ:ARDX) has gained about 353% over the past 12 months. As of the end of the first quarter of 2023, 20 hedge funds tracked by Insider Monkey were long Ardelyx, Inc. (NASDAQ:ARDX ... Plug Power, Inc. Common Stock. $9.46 -1.29 -12.00%. Ardelyx, Inc. Common Stock (ARDX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and ... Mar 2, 2023 · Ardelyx (ARDX) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.31 per share a year ago. These figures are ... WALTHAM, Mass., Dec. 29, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research of the U ...After Hours Volume: 64.24K. Close. Chg. Chg %. $4.3300. 0.3000. 7.44%. Ardelyx Inc. advanced stock charts by MarketWatch. View ARDX historial stock data and compare to other stocks and exchanges.11 thg 8, 2020 ... Ardelyx, Inc. filed an NDA for its chief asset tenapanor in the control of serum phosphorus in adults with chronic kidney disease on ...WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Find the latest Institutional Holdings data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Nov 29, 2023 · See the latest Ardelyx Inc stock price (ARDX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Nov 24, 2023 · Who is on Ardelyx's Insider Roster? The list of insiders at Ardelyx includes David M. Mott, David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell, and Susan Rodriguez. Learn more on insiders at ARDX. Instagram:https://instagram. liberty 1 dollar coin 1979comcast stock dividendbest salesforce trainingactive care plus banfield Ardelyx (NASDAQ:ARDX) is a great speculative biotech play to look into. Why is that? That's because despite its potential with two drugs in the pipeline, the stock is still trading with a very low ...Oct 18, 2023 · The FDA approved Ardelyx Inc's (NASDAQ:ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD ... stock open timebest cheap isp Dec 18, 2022 · Massachusetts-based Ardelyx (NASDAQ:ARDX) is another hot biotech to consider heading into 2023. All after the US FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of ... online banks with digital debit cards Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and ...Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of …